Your browser doesn't support javascript.
loading
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Gasparetto, Cristina; Schiller, Gary J; Tuchman, Sascha A; Callander, Natalie S; Baljevic, Muhamed; Lentzsch, Suzanne; Rossi, Adriana C; Kotb, Rami; White, Darrell; Bahlis, Nizar J; Chen, Christine I; Sutherland, Heather J; Madan, Sumit; LeBlanc, Richard; Sebag, Michael; Venner, Christopher P; Bensinger, William I; Biran, Noa; Ammu, Sonia; Ben-Shahar, Osnat; DeCastro, Andrew; Van Domelen, Dane; Zhou, Tianjun; Zhang, Chris; Bentur, Ohad S; Shah, Jatin; Shacham, Sharon; Kauffman, Michael; Lipe, Brea.
Afiliação
  • Gasparetto C; Duke University Medical Center, Durham, NC, USA. cristina.gasparetto@duke.edu.
  • Schiller GJ; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Tuchman SA; University of North Carolina, Chapel Hill, NC, USA.
  • Callander NS; Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
  • Baljevic M; University of Nebraska Medical Center, Omaha, NE, USA.
  • Lentzsch S; Colombia University, New York, NY, USA.
  • Rossi AC; NYPH Weill Cornell, New York, NY, USA.
  • Kotb R; Cancer Care Manitoba, Winnipeg, MB, Canada.
  • White D; Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
  • Bahlis NJ; Charbonneau Cancer Research Institute, Calgary, AB, Canada.
  • Chen CI; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Sutherland HJ; Vancouver General Hospital, Vancouver, BC, Canada.
  • Madan S; Banner MD Anderson Cancer Center, Gilbert, AZ, USA.
  • LeBlanc R; Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC, Canada.
  • Sebag M; Royal Victoria Hospital, Montreal, QC, Canada.
  • Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
  • Bensinger WI; Myeloma and Transplant Program, Swedish Cancer Institute, Seattle, WA, USA.
  • Biran N; Hackensack Meridian Health, Hackensack University Medical Center, Teaneck, USA.
  • Ammu S; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Ben-Shahar O; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • DeCastro A; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Van Domelen D; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Zhou T; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Zhang C; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Bentur OS; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Shah J; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Shacham S; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Kauffman M; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Lipe B; University of Rochester Medical College, Rochester, NY, USA.
Br J Cancer ; 126(5): 718-725, 2022 03.
Article em En | MEDLINE | ID: mdl-34802051
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Triazóis / Dexametasona / Hidrazinas / Mieloma Múltiplo Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Triazóis / Dexametasona / Hidrazinas / Mieloma Múltiplo Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos